ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Rare Disease

Neurogene launches to tackle rare neurological disorders

by Lisa Jarvis
February 15, 2019 | APPEARED IN VOLUME 97, ISSUE 7

 

Rare-disease-focused Neurogene has debuted with $68.5 million in its first formal round of financing from investors that include Samsara BioCapital, EcoR1 Capital, and Redmile Group. The biotech firm is developing gene therapies for rare neurological diseases and plans to use the proceeds to fund clinical studies, invest in technology, and build a viral vector production site. Neurogene, which partners with academic scientists and patient advocacy groups, is initially pursuing gene therapies for two lysosomal storage disorders and a rare form of the sensory disorder Charcot-Marie-Tooth.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment